Kooperativer Bibliotheksverbund

UID:

Format: XI, 268 p. 31 illus., 26 illus. in color. , online resource.

Edition: 1st ed. 2024.

ISBN: 9783031661525

Series Statement: Interdisciplinary Cancer Research, 8

Content: Lung cancer is one of the most common cancers and the leading cause of deaths worldwide. The eighth volume of the "Interdisciplinary Cancer Research" series, entitled "Lung Cancer Pathophysiology: An Interdisciplinary Approach" publishes comprehensive reviews on the mechanisms of lung cancer. Fundamental elements of a lung cancer multidisciplinary team are discussed. The epithelial to mesenchymal transition in lung cancer, and the roles of tumor immune microenvironment, NK cells, RNA, micro-RNA, and long-non coding RNA in lung cancer are explained. A comprehensive genomic profiling in lung cancer in the era of immunotherapy approaches is also provided in this volume. This interdisciplinary series is of special value to researchers working on oncology. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value to researchers, oncologists, and oncosurgeons who wish to extend their knowledge on lung cancer.

Note: Interdisciplinary Approach in Lung Cancers -- Fundamental Elements of a High-Functioning Lung Cancer Multidisciplinary Team (MDT) -- Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts? -- Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer -- Natural Killer Cells in Lung Cancer -- RNA-binding Proteins as a New Link Between COPD and Lung Cancer -- The Implication of miRNA Signature in the Characteristic Features and Diagnosis of Lung Cancer -- MicroRNAs in the Immunopathology and Treatment of Non-small Cell Lung Cancer -- Monitoring Exosomal Non-coding RNA in Lung Cancers -- Mediastinal Staging of Lung Cancer -- Pleural Mesothelioma: The Importance of Working Together -- Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards.

In: Springer Nature eBook

Additional Edition: Printed edition: ISBN 9783031661518

Additional Edition: Printed edition: ISBN 9783031661532

Additional Edition: Printed edition: ISBN 9783031661549

Language: English

DOI: 10.1007/978-3-031-66152-5

URL: https://doi.org/10.1007/978-3-031-66152-5

URL: Volltext  (URL des Erstveröffentlichers)

URL: lizenzpflichtig

UID:

Format: 1 online resource (272 pages)

Edition: 1st ed.

ISBN: 9783031661525

Series Statement: Interdisciplinary Cancer Research Series ; v.8

Note: Intro -- Preface -- Contents -- About the Editor -- Interdisciplinary Approach in Lung Cancers -- 1 Introduction -- 2 Epidemiology -- 3 Screening -- 4 Clinical Manifestations and Diagnosis -- 5 Classification -- 6 Treatment -- 7 Conclusion -- References -- Fundamental Elements of a High-Functioning Lung Cancer Multidisciplinary Team (MDT) -- 1 Introduction -- 1.1 Multidisciplinary Team -- 1.2 Leadership -- 1.3 Team Collaboration -- 1.4 The MDT Venue -- 1.5 Data -- 1.6 MDT Billing -- 1.7 Biobank -- 1.8 Research -- 2 Conclusion -- References -- Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts? -- 1 Introduction: EMT in Early-Stage Lung Cancer -- 2 EMT Phenotype in Early-Stage Lung Cancer -- 2.1 Regulatory Genes of EMT in Early-Stage Lung Cancer -- 2.2 Circulating Tumor Cells in Early-Stage EMT in Lung Cancer -- 2.3 Lymph Node Status and Phenotypic Transition in Early-Stage EMT -- 3 The Roles of ncRNA in EMT Regulation in Early-Stage Lung Cancer -- 3.1 miRNAs in EMT Regulation in Lung Cancer -- 3.2 lncRNAs in EMT in Early-Stage Lung Cancer -- 4 EMT as Mechanisms of Resistance to Conventional and Targeted Therapies in Lung Cancers: Correlations with Different Treatmen... -- 4.1 Adjuvant Treatment Setting as a Potential Early Time Point for EMT -- 4.2 First-Line Treatment of Advanced and Metastatic Lung Cancer Harboring Actionable Mutations as a Potential Early Time Point... -- 5 Conclusion -- References -- Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer -- 1 Introduction -- 2 Interaction Between Tumor and TIME -- 2.1 Tumor Intrinsic Factors -- 2.1.1 Immunogenic Hot Tumors -- 2.1.2 Immunosuppressive Cold Tumors -- 2.1.3 Premalignant Lesions -- 2.2 Immune Contexture -- 2.2.1 T Lymphocytes -- 2.2.2 B Lymphocytes -- 2.2.3 Natural Killer Cells -- 2.2.4 Macrophages -- 2.2.5 Neutrophils -- 2.2.6 Dendritic Cells. , 2.2.7 Myeloid-Derived Suppressor Cells (MDSCs) -- 3 Tertiary Lymphoid Structures (TLSs) -- 4 TNM-I: TNM-Immunoscore in NSCLC -- 4.1 Location and Compartments of Immune Cells Within the Tumor -- 4.2 Scoring Method: Manual or Digital? -- 4.3 Whole Slides or Tissue Microarrays -- 5 Conclusion -- References -- Natural Killer Cells in Lung Cancer -- 1 Introduction -- 1.1 Non-small-cell Lung Cancer -- 1.2 Small-Cell Lung Cancer -- 2 Natural Killer Cells -- 2.1 Development and Maturation -- 2.2 NK Cell Cytotoxicity -- 3 Natural Killer Cells and Lung Cancer -- 3.1 NK Cell-Based Immunotherapies in Lung Cancer -- 4 Conclusion -- References -- RNA-binding Proteins as a New Link Between COPD and Lung Cancer -- 1 Introduction -- 2 RNA-binding Proteins (RBPs) as Mediator of Post-transcriptional Gene Regulation (PTGR) -- 3 RBPs in COPD Pathogenesis -- 4 RBPs in Modulating the Inflammation of Lower Airways -- 5 RBPs in Modulating IL-33 Signaling Pathway and COPD -- 6 RBPs in Modulating Drugs Response in COPD -- 7 RBPs in Lung Cancer Pathogenesis -- 8 Non-small Cell Lung Cancer (NSCLC) -- 9 Small Cell Lung Cancer (SCLC) -- 10 RBPs in Modulating IL-33 Signaling Pathway and Lung Cancer -- 11 The Role of RBPs in Mechanisms Linking COPD and Lung Cancer -- 12 Conclusion -- References -- The Implication of miRNA Signature in the Characteristic Features and Diagnosis of Lung Cancer -- 1 Introduction -- 1.1 Lung Cancer -- 1.2 MicroRNA -- 1.3 Biogenesis of miRNA -- 2 Impact of miRNA Signatures in Targeting the Various Characteristics of LC -- 2.1 Sustaining Proliferative Signaling in LC -- 2.2 Evading Growth Suppressors in LC -- 2.3 Resisting Cell Death in LC -- 2.4 Enabling Replicative Immortality in LC -- 2.5 Inducing Angiogenesis -- 2.6 Activating Invasion and Metastasis in LC -- 2.7 Deregulating Cellular Energetic in LC -- 2.8 Avoiding Immune Destruction in LC. , 2.9 Tumor-Promoting Inflammation -- 2.10 Genome Instability and Mutation -- 3 MicroRNA as Diagnostic Markers in LC -- 3.1 Biomarkers -- 3.2 miRNA as Noninvasive Diagnostic Markers -- 3.3 miRNA as Biomarker in Histological Subtype Identification -- 3.4 miRNA as a Biomarker in the Differentiation of Tumors -- 4 Conclusion and Perspectives -- References -- MicroRNAs in the Immunopathology and Treatment of Non-small Cell Lung Cancer -- 1 Introduction -- 1.1 Statistics of NSCLC -- 2 sncRNAs in Development of NSCLC -- 3 sncRNAs as Markers of Efficacy of Treatment -- 4 Surgery -- 5 Radiotherapy -- 6 Chemotherapy -- 6.1 Platinum Derivatives -- 6.2 Taxanes -- 7 Immune Therapy -- 7.1 Immunopathology of NSCLC -- 7.2 EGFR -- 7.3 PD/PD-L1 -- 7.4 CTLA-4 -- 8 MicroRNA-Based Therapy -- 8.1 Application Schemas -- 9 Side Effects and Complications -- 9.1 Conventional Therapy -- 9.2 MicroRNA-Based Therapy -- 10 Conclusion -- References -- Monitoring Exosomal Non-coding RNA in Lung Cancers -- 1 Introduction -- 2 Non-coding RNAs -- 2.1 MicroRNAs -- 2.2 Long Non-coding RNAs -- 3 Exosomes -- 3.1 Exosome Biogenesis -- 3.2 Exosomes Cargo -- 3.3 Exosomes in Cancer -- 4 Non-coding RNAs as Biomarkers in Lung Cancer -- 4.1 Exosome-Derived miRNAs and Lung Cancer Proliferation -- 4.2 Exosome-Derived miRNAs and Angiogenesis -- 4.3 Exosome-Derived ncRNAs and EMT/MET -- 4.4 Exosomal miRNAs Underlying Cisplatin Resistance -- 5 Exosome-Derived miRNAs and Their Diagnostic and Clinical Relevance -- 6 Conclusion -- References -- Mediastinal Staging of Lung Cancer -- 1 Introduction -- 2 Imaging Techniques -- 3 Non-surgical Techniques: Diagnostic Procedures in Interventional Pulmonology -- 3.1 Transbronchial Needle Aspiration -- 3.2 Endobronchial Ultrasound-TBNA -- 3.3 Esophageal Ultrasound-Guided Fine Needle Aspiration -- 3.4 EBUS-TBNA and EUS-FNA Technique -- 3.5 Samples. , 3.6 Safety and Contraindications -- 3.7 Use of Combination Techniques -- 3.8 Transthoracic Needle Aspiration -- 3.9 Lymph Node Cryobiopsy -- 3.10 Rapid On-Site Evaluation -- 3.11 Endobronchial Elastography -- 4 Surgical Techniques -- 4.1 Mediastinoscopy -- 4.2 Transcervical Extended Mediastinal Lymphadenectomy -- 4.3 Video-Assisted Mediastinoscopic Lymphadenectomy -- 4.4 Video-Assisted Thoracic Surgery -- 4.5 Robotic-Assisted Thoracic Surgery -- 5 Restaging After Oncologic Therapy -- 5.1 Imaging -- 5.2 EBUS-TBNA -- 5.3 Surgical Techniques -- 6 Restaging After Surgery -- 7 Conclusion and Future Perspectives -- References -- Pleural Mesothelioma: The Importance of Working Together -- 1 Introduction -- 2 Histopathological Classification -- 3 Genetic Mutations -- 4 Gene Expression Modulation -- 5 Diagnosis -- 6 Treatment -- 7 The Importance of Working Together -- References -- Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards -- 1 Introduction -- 2 Efficacy of Immunotherapy in Advanced NSCLC Patients Harbouring EGFR Mutations or ALK Rearrangement -- 3 Efficacy of Immunotherapy in Advanced NSCLC Patients Harbouring Rare Oncogenic-Driven Alterations: The IMMUNOTARGET Registry -- 4 The Role of Molecular Tumour Boards: Experiences, Strengths and Limits -- 5 Conclusion -- References -- Index.

Additional Edition: Print version: Rezaei, Nima Lung Cancer Pathophysiology: an Interdisciplinary Approach Cham : Springer International Publishing AG,c2024 ISBN 9783031661518

Language: English